Abstract: A radioactive diagnostic agent which comprises (1) the unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound with intervention of a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--CH.sub.2 NH--) formed by the condensation between the formyl group in the polyformyl compound and the amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound with intervention of a methyleneimine linkage or a methyleneamine linkage formed by the condensation between the formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction, and (4) at least two radioactive metallic elements of which each is bonded to the chelating compound through a chelating bond.

Abstract: The present invention relates to a chemical product usable as a non-radioactive carrier which comprises (1) a unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound by a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--CH.sub.2 NH--) between a formyl group in the polyformy compound and an amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound by a methyleneimine linkage or a methyleneamine linkage between a formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction.

Abstract: A porphyrin compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each --CH.dbd.CH.sub.2, --CH.sub.2 CHJ.sub.3, --CH(O-lower alkanoyl)CH.sub.3, --CH(OR)CH.sub.3 or --CH(O-lower alkylene-OR)CH.sub.3 ; R.sub.3 is --H, --COOH, --COO-lower alkyl, --COO-lower alkylene-OR or --COO-lower alkylene-OOC-Z; R.sub.4 is --H, -lower alkyl or -lower alkylene-OR; R is --H, -lower alkyl or a residue of a polyfunctional carboxyl compound excluding a hydrogen atom therefrom; Z is a residue of the compound of the formula (I) excluding R.sub.3 therefrom; A is --CH.sub.2 -- or --CO--; and the dotted line from the gamma-position indicates no bonding or a single direct bond; and the dotted line between the 7- and 8-positions indicates the presence of a single bond or a double bond; and its complexes with a metal(s) in the porphine skeleton and/or at the residue of the polyfunctional carboxyl compound, at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.

Abstract: A porphyrin compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each --CH.dbd.CH.sub.2, --CH.sub.2 CH.sub.3, --CH(O-lower alkanoyl)CH.sub.3, --CH(OR)CH.sub.3 or --CH(O-lower alkylene-OR)CH.sub.3 ; R.sub.3 is --H, --COOH, --COO-lower alkyl, --COO-lower alkylene-OR or --COO-lower alkylene-OOC-Z; R.sub.4 is --H, -lower alkyl or -lower alkylene-OR; R is --H, -lower alkyl or a residue of a polyfunctional carboxyl compound excluding a hydrogen atom therefrom; Z is a residue of the compound of the formula (I) excluding R.sub.3 therefrom; A is --CH.sub.2 -- or --CO--; and the dotted line from the gamma-position indicates no bonding or a single direct bond; and the dotted line between the 7- and 8-positions indicates the presence of a single bond or a double bond; and its complexes with a metal(s) in the porphine skeleton and/or at the residue of the polyfuntional carboxyl compound, at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.

Abstract: A radioactive diagnostic agent which comprises (1) a unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--.sub.2 NH--) formed by the condensation between the formyl group in the polyformyl compound and the amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound by a methyleneimine linkage or a methyleneamine linkage formed by the condensation between the formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction, and (4) at least two radioactive metallic elements of which each is bonded to the chelating compound through a chelating bond.

Abstract: A radioactive diagnostic agent having high labeling efficiency, prepared by bringing an aqueous solution of a radioactive metallic element contaminated with a non-radioactive metallic ions into contact with a non-radioactive carrier comprising a carrier substance having a chelate-forming property and optionally a physiologically active substance chemically bonded thereto, at least one of said aqueous solution and said non-radioactive carrier comprising at least one reductive material chosen from ascorbic acid and erythrobic acid, and their salts and esters.

Abstract: A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, C.sub.1 -C.sub.3 alkyl or phenyl. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

Abstract: A protein-polysuccinimide complex wherein a biologically active protein is combined with a polysuccinimide having a mean molecular weight of 2,000 to 1,000,000 and consisting of constitutive units represented by the following formulae: ##STR1## Said complex can be labelled with a radio-metal and can be used as a radioactive diagnostic in the field of nuclear medicine.

Abstract: A stable non-radioactive carrier for use in production of .sup.99m Tc-labeled radioactive diagnostic agent comprising a chelating agent, a water-soluble reducing agent for pertechnetate and a stabilizer chosen from ascorbic acid and erythorbic acid, and their pharmaceutically acceptable salts and esters in an amount of more than about 100 moles per 1 mol of said water-soluble reducing agent.

Abstract: A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, C.sub.1 -C.sub.3 alkyl or phenyl. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

Abstract: A .sup.99m Tc-labeled radioactive diagnostic agent being useful for visualization and dynamic inspection of hepatobiliary ducts and having a high stability and no material toxicity, which comprises .sup.99m Tc in the form of pertechnetate and a non-radioactive carrier, the non-radioactive carrier comprising an N-pyridoxyl-.alpha.-amino acid of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each an atom or an atomic group present in the .alpha.-amino acid residue encompassed by the dotted line and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.10 alkyl group or a C.sub.1 -C.sub.10 alkyl group substituted with at least one hydrophilic group or its salt, and a reducing agent for pertechnetate.

Abstract: A radioactive diagnostic agent for bone scanning, which comprises .sup.99m Tc and a non-radioactive carrier comprising (A) at least one chosen from methanehydroxydiphosphonic acid and their salts and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1 and prevents the accumulation of radioactivity in liver so that definite diagnosis can be assured.

Abstract: A non-radioactive composition for intracorporeal labeling of red blood cells with radioactive technetium, which comprises as the essential components (a) at least one of pyridoxal and its salts, (b) at least one stannous salt and (c) at least one .alpha.-amino acid of which the administeration through a vein in a living body can assure an efficient intracorporeal labeling of red blood cells in the living body with radioactive technetium which is subsequently administered through the vein.

Abstract: A .sup.99m Tc-labeled radioactive diagnostic agent, prepared by contacting .sup.99m Tc in the form of a pertechnetate with a non-radioactive carrier comprising pyridoxal or salt thereof, a stannous salt and an .alpha.-amino acid not having any hydrophilic functional group dissolved in an aqueous medium. This diagnostic agent is suitable for the examination of hepatobiliary ducts due to its smooth transfer through the hepatobiliary ducts as well as its high stability and non-toxicity.